Eur Respir J 2005; 26:192-197
Copyright ©ERS Journals Ltd 2005
Morbidity and mortality in the surgery arm of EORTC 08941 trial
P. Van Schil,
J. Van Meerbeeck,
G. Kramer,
T. Splinter,
C. Legrand,
G. Giaccone,
C. Manegold and
N. van Zandwijk
EORTC (European Organisation for Research and Treatment of Cancer), Brussels, Belgium.
CORRESPONDENCE: P. Van Schil, Dept of Thoracic and Vascular Surgery, University Hospital of Antwerp, Wilrijkstraat 10, B2650 Edegem (Antwerp), Belgium. Fax: 32 38214396. E-mail: paul.van.schil@uza.be
Keywords: Chemotherapy, lung cancer, morbidity, mortality, neoadjuvant therapy, surgery
Received: November 7, 2004
Accepted April 30, 2005
Controversial results of surgical treatment after induction chemotherapy, especially in relation to the extent of resection, have previously been reported. Mortality and morbidity were studied in the surgical arm of the European Organisation for Research and Treatment of Cancer (EORTC) 08941 trial.
EORTC 08941 is a multicentre, prospective, randomised, phase-III trial of surgical resection versus radiotherapy in patients with proven stage IIIA-N2 nonsmall cell lung cancer after an objective response to platinum-based induction chemotherapy. Operative results in the 167 patients randomised in the surgical arm are presented within this study. Among these patients, one switched to the radiotherapy arm and 17 patients did not get any protocol treatment or information is not yet available.
Radical resection with negative surgical margins was obtained in 74 patients (49.7%). In 61 patients (40.9%), a pathological down-staging to N0 or N1 was present. Operative 30-day mortality was 4.0%. Post-operative complications were mainly pneumonia, respiratory insufficiency, arrhythmias, air leak, cardiac decompensation, empyema and bronchopleural fistula. In total, 12 (8.1%) patients underwent re-operation due to positive margins, haemothorax, empyema and bronchopleural fistula.
In conclusion, surgical resection after induction chemotherapy in the multicentre European Organisation for Research and Treatment of Cancer trial has yielded acceptable rates of morbidity and mortality.
This article has been cited by other articles:

|
 |

|
 |
 
A. W. Kim, L. P. Faber, W. H. Warren, S. Basu, S. C. Wightman, J. A. Weber, P. Bonomi, and M. J. Liptay
Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter?
Ann. Thorac. Surg.,
September 1, 2009;
88(3):
937 - 943.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Brunelli, A. Charloux, C. T. Bolliger, G. Rocco, J-P. Sculier, G. Varela, M. Licker, M. K. Ferguson, C. Faivre-Finn, R. M. Huber, et al.
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
Eur. Respir. J.,
July 1, 2009;
34(1):
17 - 41.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Gudbjartsson, E. Gyllstedt, A. Pikwer, and P. Jonsson
Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy
Ann. Thorac. Surg.,
August 1, 2008;
86(2):
376 - 382.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. E. Van Schil
Mortality associated with pneumonectomy after induction chemoradiation versus chemotherapy alone in stage IIIA-N2 non-small cell lung cancer
J. Thorac. Cardiovasc. Surg.,
March 1, 2008;
135(3):
718 - 718.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. E. Van Schil
Operative risk of pneumonectomy after induction chemoradiotherapy
Eur. J. Cardiothorac. Surg.,
September 1, 2007;
32(3):
550 - 550.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Van Schil and J. Van Meerbeeck
Response: Re: Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non Small-Cell Lung Cancer
J Natl Cancer Inst,
August 1, 2007;
99(15):
1210 - 1211.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Uy, G. Darling, W. Xu, Q.-L. Yi, M. De Perrot, A. F. Pierre, T. K. Waddell, M. R. Johnston, A. Bezjak, F. A. Shepherd, et al.
Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer
J. Thorac. Cardiovasc. Surg.,
July 1, 2007;
134(1):
188 - 193.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Venuta, M. Anile, D. Diso, M. Ibrahim, T. De Giacomo, M. Rolla, V. Liparulo, and G. F. Coloni
Operative complications and early mortality after induction therapy for lung cancer
Eur. J. Cardiothorac. Surg.,
April 1, 2007;
31(4):
714 - 717.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. van Meerbeeck, G. W. P. M. Kramer, P. E. Y. Van Schil, C. Legrand, E. F. Smit, F. Schramel, V. C. Tjan-Heijnen, B. Biesma, C. Debruyne, N. van Zandwijk, et al.
Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer
J Natl Cancer Inst,
March 21, 2007;
99(6):
442 - 450.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Mansour, E. A. Kochetkova, X. Ducrocq, M.-D. Vasilescu, G. Maxant, A. Buggenhout, J.-M. Wihlm, and G. Massard
Induction chemotherapy does not increase the operative risk of pneumonectomy!
Eur. J. Cardiothorac. Surg.,
February 1, 2007;
31(2):
181 - 185.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Fujita, N. Katakami, Y. Takahashi, K. Hirokawa, A. Ikeda, C. Tabata, T. Mio, and M. Mishima
Postoperative complications after induction chemoradiotherapy in patients with non-small-cell lung cancer.
Eur. J. Cardiothorac. Surg.,
June 1, 2006;
29(6):
896 - 901.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Jett and Y. E. Miller
Update in lung cancer 2005.
Am. J. Respir. Crit. Care Med.,
April 1, 2006;
173(7):
695 - 697.
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the European Respiratory Society.
|